CLDN18.2×HER2 bispecific ADC / Dong-A - LARVOL DELTA

Overcoming target heterogeneity in gastric cancer with an eKiH-engineered CLDN18.2×HER2 bispecific ADC (AACR 2026) - "We previously developed DA3501 (AT-211), a CLDN18.2-targeting ADC currently advancing toward Phase 1 evaluation. The DA3501 antibody clone demonstrates enhanced affinity and internalization compared with zolbetuximab... This BsAb is a rationally engineered CLDN18.2×HER2 bispecific ADC designed to overcome target heterogeneity in GC. Together with the DA3501 program, it broadens therapeutic coverage of CLDN18.2/HER2-expressing tumors and combination-strategy studies, including ICI co-therapy."

ADC • Bispecific • Heterogeneity • IO biomarker • Gastric Cancer • Oncology • Solid Tumor • CLDN18 • HER-2